About the event
In 2018, Professor of Neurology, Dr. Dale Bredesen, along with medical colleagues from 15 other clinics, published a paper describing 100 patients with cognitive decline who had well documented, quantified improvements in cognition using his targeted, multi-component programme. These new results expand on Professor Bredesen’s earlier published case studies of 10 patients, 9 of whom showed sustained subjective and objective improvement in cognition using his approach.
In the last 7 years, over 3000 patients have used The Bredesen Protocol; patient outcomes have resulted in the protocol evolving and it is now possible to identify key elements that differentiate between best outcomes and lesser outcomes.
This practitioner seminar will focus on the many nutritional, metabolic, toxic, and inflammatory parameters that are critical to the assessment and optimal treatment of patients with cognitive decline or risk for cognitive decline. It will cover the specifics in terms of optimising outcomes as well as how the protocol is being used for other neurodegenerative diseases.
Saturday April 6th 201910am – 4.00pm
The Grange Tower Bridge Hotel, 45 Prescot St, London E1 8GP
A healthy lunch and refreshments will be provided on the day.
All bookings must be made online via the link below, however if you do have any general queries,
please get in touch.
Telephone: 01684 310099
|10.00 – 11.15||Session 1: Cognitive decline: background and concepts|
|11.15 – 11.45||Coffee|
|11.45 – 13.00||Session 2: Reversal of cognitive decline in Alzheimer’s and pre-Alzheimer’s (MCI and SCI)|
|13.00 – 14.00||Lunch|
|14.00 – 15.30||Session 3: Prevention and reversal of neurodegenerative diseases|
|15.30 – 16.00||Questions|
|16.00||Coffee and networking|
The speaker: Dr. Dale Bredesen
Professor Bredesen, Professor of Molecular and Medical Pharmacology at UCLA and Founding President and Professor Emeritus at the Buck Institute for Research on Aging, has spent over 30 years researching the basic mechanisms of neurodegeneration. He and his research group have published over 220 research papers, and he has developed a novel approach to treatment and prevention of Alzheimer’s disease, utilising precision medicine programs rather than outmoded monotherapeutics.